Chu L, Bradley RM, Auerbach P, Abitbol A, et al. Real-world impact of adding a glucagon-like peptide-1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium-glucose co-transporter-2 inhibitor: Diabetes Obes Metab 2024 Aug 7. doi: 10.1111/dom.15834.
PMID: 39113258